Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 4, 2007, Pages 477-484

  Yanagisawa, Yoko ^a   Maruta, Fukuto ^a   Iinuma, Nobuyoshi ^a   Ishizone, Satoshi ^a   Koide, Naohiko ^a   Nakayama, Jun ^a   Miyagawa, Shinichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Response rate; Sialyl Lewis X; Thymidylate synthase; Toxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; PARAFFIN; SIALYL LEWIS X ANTIGEN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLON RESECTION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENT CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD15; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; OLIGOSACCHARIDES; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; SURVIVAL RATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; VITAMIN B COMPLEX;

EID: 34147189071     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600994418     Document Type: Article

References (18)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000;343:905-14.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
4. Johnston PG, Lenz HJ, Leichhman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
5. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwarz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase(platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-6.
6. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res 2000;6:1322-7.
7. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92.
8. Grabowski P, Mann B, Mansmann U, Lövin N, Foss HD, Berger G, et al. Expression of SIALYL-Le(X) antigen defined by Mab AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 2000;15:281-6.
9. Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T, Fukuda M. Carcinoma-associated expression of core 2 beta-1,6-N- acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res 1997;57:5201-6.
10. Baldus SE, Mönig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis (a) and sialyl-Lewis (x) antigens in colorectal adenocarcinoma. Histopathology 2002;40:440-9.
11. Kobayashi M, Mitoma J, Nakamura N, Katsuyama T, Nakayama J, Fukuda M. Induction of peripheral lymph node addressin in human gastric mucosa infected by Helicobacter pylori. Proc Natl Acad Sci USA 2004;101:17807-12.
12. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, et al. Telomerase reverse transcriptase expression Is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
13. Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
14. Kurebayashi J, Nishimura R, Tanaka K, Kohno K, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004;11:389-95.
15. Yamaguchi A, Kurosaka Y, Ishida T, Nishimura G, Kanno M, Kosaka T, et al. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991;34:921-4.
16. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-9.
17. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metatatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
18. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl Lewis X antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993;53:3632-7.